Rice, Meghan A.

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1

Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., et al. (2020) · Proceedings of the National Academy of Sciences

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 146

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Koltun, E. S., Rice, M. A., Gustafson, W. C., Wilds, D., Jiang, J., Lee, B. J., Wang, Z., Chang, S., Flagella, M., Mu, Y., et al. (2022) · Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 34

Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

Koltun, E., Cregg, J., Rice, M. A., Whalen, D. M., Freilich, R., Jiang, J., Hansen, R., Bermingham, A., Knox, J. E., Dinglasan, J., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 33

Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.

Gustafson, W. C., Wildes, D., Rice, M. A., Lee, B. J., Jiang, J., Wang, Z., Chang, S., Flagella, M., Mu, Y., Dinglasan, N., et al. (2022) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingPancreatic and Hepatic Oncology Research

Cited by 28